CBFB and acute myeloid leukemia: Thus, careful patient selection is crucial for optimal GO usage, a point further strengthened by a 25-year retrospective analysis of outcome determinants in CBFb-mutated AML (a favourable risk group) in the UK, presented by Alan Burnett.